Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

NCT00069238 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, T-Cell
Lymphoma, Extranodal NK-T-Cell

Interventions

BIOLOGICAL: Alemtuzumab (Campath)
DRUG: EPOCH

Sponsor

National Cancer Institute (NCI)